Gilead Sciences, Inc. vs Eli Lilly and Company
A head-to-head of Gilead Sciences, Inc. (GILD) and Eli Lilly and Company (LLY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | GILD | LLY |
|---|---|---|
| Market Cap | $166.72B | $823.33B |
| P/E (TTM) | 18.29 | 41.89 |
| Forward P/E | 13.83 | 26.25 |
| P/S | 5.61 | 11.40 |
| P/B | 7.12 | 35.66 |
| EV/EBITDA | 12.15 | 22.78 |
| Dividend Yield | 2.42% | 0.50% |
| Profit Margin | 30.99% | 34.99% |
| Gross Margin | 78.83% | 83.04% |
| Operating Margin | 39.74% | 45.56% |
| Revenue Growth (YoY) | +4.39% | +55.54% |
| FCF Yield | 6.13% | 1.26% |
| Debt / Equity | 94.64 | 139.02 |
| Current Ratio | 1.97 | 1.50 |
Which is better: Gilead Sciences, Inc. or Eli Lilly and Company?
- ✓Larger by market cap: Eli Lilly and Company
- ✓Cheaper valuation (lower P/E): Gilead Sciences, Inc.
- ✓Higher dividend yield: Gilead Sciences, Inc.
- ✓More profitable (net margin): Eli Lilly and Company
- ✓Faster revenue growth: Eli Lilly and Company
- ✓Higher free-cash-flow yield: Gilead Sciences, Inc.
Across 13 available metrics, Gilead Sciences, Inc. leads 9–4.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Gilead Sciences, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.